Peter McCullough on health: what the evidence says · JRE #1747
SUBJECT: HEALTH
Not a true/false call. Every claim is logged with its sources; read the exhibits below.
in a randomized trial by Chowdhury and colleagues from Bangladesh, 303 patients randomized to this viral cytotherapy, which is all topical, no prescription drugs, nothing else needed, versus a control group
What the evidence says 01 / RECORD
A Bangladesh randomized trial matching this description (Chowdhury, Arefin, Fattah Rumi et al., Indian Journal of Otolaryngology and Head & Neck Surgery, 2021) randomized 189 confirmed COVID-19 patients, not 303, into seven arms of povidone-iodine nasal irrigation or spray versus distilled-water controls, and measured only short-term nasopharyngeal viral clearance by repeat PCR in already-infected individuals; it made no claim about, and provides no evidence for, national-level case reduction. National surveillance data show Bangladesh did not approach near-zero COVID-19 transmission during this period: the country recorded its highest single-day death tolls of the pandemic in July 2021 (201 deaths on July 7, rising to 247 and 257 later that month) amid a Delta-variant-driven third wave, with monthly deaths roughly quadrupling from the prior year's average while under 3% of the population was fully vaccinated. No population-level study links widespread povidone-iodine use to Bangladesh's epidemic curve, and the antiseptic trial itself was a small hospital-based clearance study, not a national intervention program. The claim that Bangladesh reached near-zero COVID-19 via an oral-nasal antiseptic protocol is not supported by the cited trial or by national epidemiological data.